Navigating the Future: Nanotechnological Strategies for Tackling Hepatocellular Carcinoma

Annu Kumari
{"title":"Navigating the Future: Nanotechnological Strategies for Tackling Hepatocellular Carcinoma","authors":"Annu Kumari","doi":"10.47363/jcrr/2023(5)180","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC), a widely prevalent form of liver malignancy, is a leading contributor to cancer-related mortality globally, despite advances in preventive and diagnostic technologies. It is closely associated with cirrhosis, with major contributions from hepatitis B and C infections and alcohol consumption. Early detection of HCC is crucial as it is often diagnosed at an asymptomatic stage. Radiological screenings and serological markers are effective methods of achieving early detection. Various surgical methods, including liver transplantation, and therapies such as radiofrequency lesioning and chemoembolization, are employed to treat this disease. However, due to limited donor availability and late diagnosis, treatment can be delayed. Tumour size, liver disease severity, and patient’s overall health are among the factors that influence the disease. Nanotechnology, a field that involves the precise manipulation of materials at the nanometer scale and the targeted delivery of therapeutic agents, presents a promising solution for HCC therapy. The utilization of nanoparticle-based therapies allows for the specific targeting of tumour-associated antigens, which enhances drug delivery and reduces drug-induced toxicity. Furthermore, nanomaterials such as carbon nanoparticles and biochemical sensors aid in the detection of oncological markers. Nanomedicine-based approaches possess the potential to revolutionize HCC therapy by improving drug delivery and targeting liver cancer stem cells. Specifically, targeted ligand-mediated therapy using saccharide or polysaccharide compounds, antibodies, peptides, and aptamers shows promise for liver-specific HCC treatment. Additionally, nanotherapy aimed at liver cancer stem cells (LCSCs) provides new possibilities to overcome the limitations of conventional treatments and improve patient outcomes. Ultimately, nanotechnology-based approaches hold great potential in enhancing the effectiveness of HCC therapy and offer new avenues for precision medicine in cancer treatment.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research Reviews & Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47363/jcrr/2023(5)180","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatocellular carcinoma (HCC), a widely prevalent form of liver malignancy, is a leading contributor to cancer-related mortality globally, despite advances in preventive and diagnostic technologies. It is closely associated with cirrhosis, with major contributions from hepatitis B and C infections and alcohol consumption. Early detection of HCC is crucial as it is often diagnosed at an asymptomatic stage. Radiological screenings and serological markers are effective methods of achieving early detection. Various surgical methods, including liver transplantation, and therapies such as radiofrequency lesioning and chemoembolization, are employed to treat this disease. However, due to limited donor availability and late diagnosis, treatment can be delayed. Tumour size, liver disease severity, and patient’s overall health are among the factors that influence the disease. Nanotechnology, a field that involves the precise manipulation of materials at the nanometer scale and the targeted delivery of therapeutic agents, presents a promising solution for HCC therapy. The utilization of nanoparticle-based therapies allows for the specific targeting of tumour-associated antigens, which enhances drug delivery and reduces drug-induced toxicity. Furthermore, nanomaterials such as carbon nanoparticles and biochemical sensors aid in the detection of oncological markers. Nanomedicine-based approaches possess the potential to revolutionize HCC therapy by improving drug delivery and targeting liver cancer stem cells. Specifically, targeted ligand-mediated therapy using saccharide or polysaccharide compounds, antibodies, peptides, and aptamers shows promise for liver-specific HCC treatment. Additionally, nanotherapy aimed at liver cancer stem cells (LCSCs) provides new possibilities to overcome the limitations of conventional treatments and improve patient outcomes. Ultimately, nanotechnology-based approaches hold great potential in enhancing the effectiveness of HCC therapy and offer new avenues for precision medicine in cancer treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
领航未来:应对肝细胞癌的纳米技术战略
肝细胞癌(HCC)是一种广泛流行的肝脏恶性肿瘤,尽管预防和诊断技术不断进步,但它仍是导致全球癌症相关死亡率的主要因素。它与肝硬化密切相关,乙型肝炎和丙型肝炎感染以及饮酒也是主要诱因。早期发现 HCC 至关重要,因为它通常是在无症状阶段被诊断出来的。放射学筛查和血清学标记是实现早期发现的有效方法。目前已采用包括肝移植在内的各种手术方法以及射频病变和化疗栓塞等疗法来治疗这种疾病。然而,由于供体有限和诊断较晚,治疗可能会延误。肿瘤大小、肝病严重程度和患者的整体健康状况都是影响该疾病的因素。纳米技术是一个涉及在纳米尺度上精确操纵材料和靶向输送治疗剂的领域,它为 HCC 治疗提供了一种前景广阔的解决方案。利用基于纳米粒子的疗法可以对肿瘤相关抗原进行特异性靶向治疗,从而增强药物输送并降低药物毒性。此外,碳纳米粒子和生化传感器等纳米材料有助于检测肿瘤标志物。基于纳米药物的方法通过改善给药和靶向肝癌干细胞,具有彻底改变 HCC 治疗的潜力。具体来说,使用糖或多糖化合物、抗体、肽和适配体进行配体介导的靶向治疗有望用于肝脏特异性 HCC 治疗。此外,针对肝癌干细胞(LCSCs)的纳米疗法为克服传统疗法的局限性和改善患者预后提供了新的可能性。最终,基于纳米技术的方法在提高 HCC 治疗效果方面具有巨大潜力,并为癌症治疗中的精准医学提供了新途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Navigating the Future: Nanotechnological Strategies for Tackling Hepatocellular Carcinoma Efficacy of Individualized Cancer Management Metastatic Tumors of Unknown Primary (Muos) Definition, Frequency and General Considerations A Study to Assess the Effect of Structured Teaching Programme on Knowledge of Patients with Acute Myeloid Leukaemia on Chemotherapy Schedule, Side Effects and its Management at a Tertiary Cancer Centre Unraveling the Cancer Metabolism: Fasting Reset, Ketogenic Diet? and Therapeutic Strategies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1